GlassScriptPhysician profile
Nicholas Tzikas
NPI 1174880538
$45,978.27
in general payments reported to CMS, 2019-2025
13 companies · $30K in 2025
The $30K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $275 · 2020: $17.20 · 2021: $469 · 2022: $1,050 · 2023: $645 · 2024: $13K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Consulting Fee: $15K · Food and Beverage: $2,940 · Honoraria: $1,438 · Travel and Lodging: $1,184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,500.00 |
| Consulting Fee | $15,106.50 |
| Food and Beverage | $2,939.84 |
| Honoraria | $1,437.50 |
| Travel and Lodging | $1,183.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $37,901.35 | 2023-2025 | |
| Abbvie INC. | $4,626.38 | 2021-2025 | Qulipta |
| Axsome Therapeutics, INC. | $1,495.00 | 2025 | Symbravo |
| Lundbeck LLC | $463.62 | 2019-2024 | Vyepti |
| Biohaven Pharmaceutical Holding Company LTD. | $437.61 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $361.87 | 2020-2021 | |
| Amgen INC. | $207.52 | 2019-2021 | |
| Hinge Health, INC. | $135.00 | 2024 | Enso |
| Impel Pharmaceuticals INC. | $116.56 | 2022-2023 | Trudhesa |
| Tonix Medicines, INC. | $95.75 | 2024 | Zembrace Symtouch |
| Biogen, INC. | $85.00 | 2023 | Vumerity |
| Abbott Laboratories | $45.70 | 2024 | Mitraclip |
| Impel Pharmaceuticals LLC | $6.91 | 2024 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Tzikas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.